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Abstract
OBJECTIVE: Bax protein is a key mediator of apoptosis, and it might be related to chemosensitivity. The purpose of
this study was to evaluate the prognostic role of Bax in patients with advanced gastric cancer treated with triplet
chemotherapy COI regimen (capecitabine, oxaliplatin, and irinotecan).METHODS: Pretreatment tissue blocks were
available for 23 consecutive patients, selected for good performance status (ECOG ≤ 1) and consenting for treat-
ment with first-line COI at a single institution. Bax levels were classified as positive or negative by immunohisto-
chemistry (bax N20; Santa Cruz Biotechnology) and related to outcome in terms of response rate, progression-free
survival, and overall survival. RESULTS: Bax-negative and -positive samples were 26% and 74%, respectively. Bax
expression was associated with significantly higher response rate (87% vs 33%), progression-free survival (8.7 vs
4.9 months, P = .016), and overall survival (23.8 vs 12.7 months, P = .025). In multivariate analysis including Bax
and performance status, low Bax independently predicted worse outcome, along with suboptimal performance
status. CONCLUSIONS: In advanced gastric cancer, Bax expression was related to clinical benefit with COI regimen.
Whether Bax is a prognostic or mixed prognostic/predictive factor warrants prospective confirmation. It is to be
defined if Bax predicts sensitivity to platinum analogs or to whatever chemotherapy regimen.
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Introduction
Despite decreasing incidence, gastric cancer is still the second most
common cause of cancer-related death in the world [1]. Even if radical
resection is the mainstay of curative treatment of gastric cancer, dis-
ease recurrence is very common. Outcome of unresectable or meta-
static gastric cancer is still extremely poor, although chemotherapy
demonstrated to confer a benefit in terms of survival and quality of
life [2]. There is no standard first-line chemotherapeutic regimen,
although cisplatin and fluoropirimidine combination is the backbone
of treatment, with or without other agents such as epirubicin or doc-
etaxel [3]. Recently, oxaliplatin and capecitabine are replacing cisplatin
and 5-fluorouracil, with equivalent efficacy and significantly less acute
toxicity [4]; irinotecan has proven activity, and clinical outcome has
certainly improved by combination of the most active drugs and with
the addition of the targeted agent trastuzumab for a subset of patients
with HER2-positive disease [5].
We previously conducted a phase 1/2 study of capecitabine in com-
bination with oxaliplatin and irinotecan (COI regimen) to find the
maximum tolerated dose and to evaluate the activity of the triplet
in patients with advanced colorectal cancer [6]. The COI regimen
was administered every other week and was designed to maximize
the dose of irinotecan and sequence-dependent synergistic interactions
among the three drugs, while giving capecitabine and oxaliplatin at
fixed, clinically relevant doses. On the basis of our preliminary data,
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we conducted a phase 2 study with COI as first-line treatment in
patients with advanced gastric cancer selected for good performance
status, demonstrating the safety and promising activity of this triplet
regimens [7].
Apoptosis-regulating proteins and DNA-repairing enzymes are
ideal candidates for clinical and pathologic studies investigating pre-
dictive and prognostic biomarkers. Preclinical studies documented
that exposure of cells to a variety of cytotoxic agents including plat-
inum analogs is associated with the typical morphologic changes of
apoptosis [8]. Thus, it was hypothesized that an intact apoptotic
pathway is necessary for chemotherapy-induced cell death and, con-
versely, that abnormalities in the ability of a cell to undergo apoptosis
may lead to the development of chemoresistance. The apoptotic cell
death is regulated by a genetic program involving both effectors and
repressors. Bax is a proapoptotic Bcl-2 family member and is induced
by functional p53 to counter the death repressor activity of both Bcl-2
and Bcl-XL, with the consequence to accelerate cell death induced by
growth factors withdrawal and chemotherapy drugs [8–10]. Apopto-
sis depends on the relative amount of Bcl-2 and Bax homodimers and
heterodimers present in the cell, and sensitivity to cytotoxic agents
such as platinum analogs is favored when increased mitochondrial
concentration of Bax/Bax homodimers occurs [11,12]. This observa-
tion raises the possibility that reduced levels of downstream molecules
such as Bax may render cancer cells resistant to chemotherapy-induced
apoptosis, even in a p53-independent manner.
The aim of this study was to investigate the prognostic and predic-
tive significance of Bax in a series of patients homogeneously treated
with the triplet regimen consisting of irinotecan added to standard
fluoropyrimidine and oxaliplatin-based chemotherapy.
Materials and Methods
Patients and Treatment
The investigation was conducted as a mono-institutional, prospec-
tive phase 2 study at Istituto Nazionale dei Tumori of Milan. Patients
with chemonaive advanced gastric cancer were treated with COI reg-
imen (irinotecan 180 mg/m2 infused during 90 minutes on day 1,
followed by oxaliplatin 85 mg/m2 in a 3-hour infusion on day 2
and capecitabine 1000 mg/m2 per day orally twice daily from days
2 to 6 of a biweekly schedule) [13]. Treatment was continued until
disease progression or unacceptable toxicity, for a maximum of up to
eight cycles. Each patient provided a written informed consent before
being enrolled in the study. Eligible patients had histologically con-
firmed inoperable or metastatic adenocarcinoma of the stomach or
gastroesophageal junction, aged between 18 and 70 years, an Eastern
Cooperative Oncology Group (ECOG) performance status score of
0 to 1, and a life expectancy of at least 3 months. Other inclusion
criteria were measurable disease according to Response Evaluation
Criteria in Solid Tumors (RECIST) and adequate hematologic, renal,
and hepatic functions. No prior chemotherapy was allowed, except
adjuvant chemotherapy, which had to be completed at least 6 months
before treatment. Patients were excluded from study if they had any
other active malignancy with the exception of nonmelanoma skin
cancer or in situ cervical cancer or had documented brain metastases,
uncontrolled cardiac disease, or other clinically significant, uncon-
trolled coexisting illness.
Clinical response was assessed every 8 weeks with radiologic exam-
ination (computed tomodensitometry or magnetic resonance imag-
ing). The Response Evaluation Criteria in Solid Tumors (RECIST)
were adopted for evaluation and objective tumor response was classi-
fied into partial response, stable disease, and progressive disease (PD)
[14]. Patients with stable disease or progressive disease were defined as
nonresponders. Response to therapy was also evaluated retrospectively
by independent radiologists.
Bax Immunohistochemical Analysis
Immunohistochemical staining of formalin-fixed, paraffin-embedded
tissue was performed for primary tumor obtained by endoscopic biopsy
or gastrectomy. In patients with recurrent disease, tumor tissue from
metastatic lesions was preferentially used for staining, if it was not avail-
able. Bax expression was assessed by immunohistochemistry (IHC)
with a rabbit polyclonal antiserum specific for the amino-terminal of
Bax (bax N-20; Santa Cruz Biotechnology, Santa Cruz, CA); all blocks
were fixed in 10% formalin and embedded in paraffin, and serial sec-
tions were cut from each block in 4 μm, stained with hematoxylin and
eosin, and confirmed pathologically. Immunohistochemical staining
for Bax protein was performed using a streptavidin-peroxidase tech-
nique with the following procedure: tissue sections were deparaffinized
in xylene and hydrated in serial alcohol solutions, respectively; endog-
enous peroxidase was blocked by incubation in 0.3% hydrogen perox-
ide in methanol for 20 to 30 minutes. Specimens were subjected to a
10-mM sodium citrate buffer, pH 6.0 for antigen retrieval (pH 6.0),
and heated in an autoclave for 6 minutes (95°C). Slides were incubated
with a 1:200 dilution of the primary rabbit antihuman Bax polyclonal
antibody (bax N-20; Santa Cruz Biotechnology) for 1 hour at room
temperature. A biotin-streptavidin detection system was used with di-
aminobenzidine as the chromogen. After several rinses in phosphate-
buffered saline (PBS), sections were incubated with the linking reagent
(biotinylated goat secondary antibodies) at room temperature for 30min-
utes, followed by rinsing in PBS and incubation for 30 minutes with the
peroxidase-conjugated streptavidin. After rinsing in PBS, the slides were
incubated in peroxidase substrate solution containing hydrogen peroxide
and 3′,3′-diaminobenzidine for 2 minutes. With each batch of test
samples, lymphocytes in the germinal center of normal lymph nodes
were evaluated as positive control; negative controls were performed
by the omission of the primary antibody during the process of staining.
Bax cytoplasmic staining was examined by two independent and blinded
senior pathologists and quantified using a visual grading system based on
the extent of staining (by percentage of positive tumor cells graded on a
scale of 0-3: 0 = none, 1 = 1%-10%, 2 = 11%-50%, 3 = 51%-100%)
and the intensity of staining (graded on a scale of 0-1 for no or weak
staining and 2-3 for moderate or strong staining). A semiquantitative
was obtained by multiplying the grades of extent and intensity of staining
and the median value was chosen as the cutoff for dichotomizing expres-
sion (Figure 1, A and B). Sections were examined at five selected non-
overlapping high-power fields (magnification, ×40) to assess the
proportion of cells that had cytoplasmic reaction.
Statistical Analysis
Descriptive statistical methodology was used to analyze the results.
All patients who had received at least one cycle of the study treatment
were included in analyses of response, safety, and survival on an
intention-to-treat basis. Results were reported with 95% confidence
intervals (CIs). Progression-free survival (PFS) was measured from
date of treatment until date of progression or death from any cause,
and overall survival (OS) was measured from the date of starting
treatment to the time of death from any cause.
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Associations between Bax status and clinical response (by RECIST
criteria) was assessed by two-tailed Fisher exact test. Survival curves
were plotted by the Kaplan-Meier method and compared by log-rank
test. For ordinal variables, a log-rank test of trend was applied. Cox
regression model with a backward stepwise procedure was done for
multivariate survival analysis [14].
Results
Patients’ Characteristics
From January 2009 to November 2010, 41 consecutive patients
with advanced gastric cancer were considered eligible for intensive
triplet chemotherapy and received first-line COI at a single Institu-
tion. Tissue blocks were available for 23 patients, whose characteris-
tics are shown in Table 1. Twenty-one subjects had measurable
disease according to RECIST criteria, whereas only two subjects had
evaluable nonmeasurable lesions and were not included in response
assessment. Only four patients with recurrent disease received prior
adjuvant chemotherapy (5-fluorouracil monotherapy in one, cisplatin-
and fluoropyrimidine-based in three cases); the remaining 19 subjects
presented with metastatic disease at the time of diagnosis. Among the
patients with initially metastatic disease, 4 of 17 underwent palliative
gastrectomy, whereas 2 of 6 patients with recurrence received resection
of metastatic lesions.
Correlation of Bax with Clinical Outcome
Among all 23 evaluated tumor specimens, 6 (26%) were Bax neg-
ative and 17 (74%) were considered as Bax positive. In the univariate
analysis, there was no statistically significant association between
Bax-negative expression and age (≤65 vs >65 years, 26% vs 25%;
P = 1), sex (male vs female, 15% vs 40%; P = .34), and histologic
subtype (intestinal vs diffuse type, 16% vs 36%; P = .37); interest-
ingly, all patients with low Bax expression were affected by high-
grade or undifferentiated gastric cancers.
The relationship between Bax expression and clinical outcome was
evaluated in terms of objective tumor response, PFS, and OS. Over-
all, 15 (71%) of 21 evaluable patients responded to COI regimen (in
particular, 11 partial responses and 4 complete responses were
observed). Only two (33%) of six patients in the Bax-negative tumors
group showed a response, and consequently, the response rate in
patients with Bax-positive expression was 87% (P = .03). Therefore,
low Bax expression was significantly associated with the lack of response
to chemotherapy.
With a median follow-up of 24 months, COI regimen produced a
7-month median PFS and a promising 18-month median OS in good-
intermediate performance status advanced gastric cancer patients. By
Cox univariate analysis of survival, we showed that patients with
Bax-negative tumors had a worse clinical outcome in terms of PFS com-
pared with Bax-positive tumors (P = .016; median, 4.9 vs 8.7 months;
hazard ratio [HR] = 3.40, CI = 1.17-9.93; Figure 2). Similarly, the OS
of patients with low Bax expression was significantly shorter compared
with those patients with a Bax-positive tumor (P = .025; median, 12.7
vs 23.8 months; Figure 3).
In multivariate analysis including Bax and PS, significantly higher
risks for progression (HR = 4.51, CI = 1.30-15.6, P = .02) and death
(HR = 6.69, CI = 1.30-15.6, P = .01) were showed for Bax-negative
Figure 1. Representative immunohistochemical detection of BAX in
two gastric adenocarcinoma samples. (A) Bax cytoplasmic immuno-
staining in well-differentiated tubular gastric adenocarcinoma and in
germinal center (positive control). Magnification, ×10. (B) Bax cyto-
plasmic immunostaining in moderately differentiated metastatic
tubular gastric adenocarcinoma. Magnification, ×20.
Table 1. Patients’ Characteristics.
Main Characteristics
Age (year)
Median 56
Range (41–70)
Sex, n (%)
Male 13 (57)
Female 10 (43)
ECOG performance status, n (%)
0 16 (70)
1 7 (30)
Disease status, n (%)
Primary metastatic 17 (74)
Recurrent 6 (26)
Location of tumor, n (%)
Proximal 8 (45)
Mid/distal 15 (65)
Lauren classification, n (%)
Diffuse 11 (48)
Intestinal 12 (52)
Differentiation, n (%)
Well/moderate 6 (26)
Poor 17 (74)
Adjuvant chemotherapy, n (%)
Yes 4 (17)
No 19 (83)
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tumors, and suboptimal PS (ECOG 1) was associated with a trend
for worst overall survival (P = .08).
Discussion
The independent validation of predictive biomarkers is a significant
issue for oncologists to treat patients who are more likely to obtain a
benefit and avoid potential toxicity in case of refractoriness. At pres-
ent, only clinical prognostic factors are currently available to drive the
treatment decision making in advanced gastric cancer [15]; very little
is available in terms of reliable prognostic indicators of response to
chemotherapy and clinical outcome, whereas the most promising pre-
dictive factors still need to be validated in large and randomized trials.
Up to now, the role of Bax seems more prognostic than predictive.
As matter of fact, it was mainly studied in patients who underwent
curative surgery for gastric cancer and was correlated to pathologic
characteristic and risk of disease relapse and death. In a surgical series
of 57 resected gastric cancer specimens, a strong relationship between
decreased Bax expression and diffuse-type gastric or poorly differenti-
ated morphology was identified [16]. Bax-negative expression was
associated with dedifferentiation, lymph node metastases, and poor
clinical prognosis in a different series of 47 resected gastric cancer
[17]. Moreover, the role of the low expression of Bax as a poor prog-
nostic factor has been reported in several malignancies treated with
chemotherapy or chemoradiotherapy, such as breast, ovarian, and
head and neck cancer [18–20]. At present, few data have been pub-
lished so far on the prognostic and/or predictive role of Bax as a bio-
marker in advanced gastroesophageal cancers treated with chemotherapy.
Low Bax expression assessed by IHC was identified as an independent
prognostic factor of poor outcome in locally advanced esophageal cancer
patients treated with cisplatin- and 5-fluorouracil–based concurrent
chemoradiotherapy [21]. Although previous analyses showed inconsis-
tent results about the role of Bax in gastric cancer [22,23], a recent ret-
rospective study in 72 patients treated with 5-fluorouracil, leucovorin,
and oxaliplatin (FOLFOX-4 regimen) for advanced disease finally docu-
mented a significant association between low Bax expression and poor
overall survival in terms of prognosis, in both univariate and multivariate
analysis; nevertheless, Bax expression failed to show a predictive role in
terms of response rate in patients with measurable disease [24]. In the
present study, we evaluated the role of Bax as potential mediator of
chemoresistance in gastric cancer treated with a highly active first-line
triplet regimen. In fact, low Bax expression could be associated with
more aggressive clinical evolution of the disease and possibly lack of
benefit from palliative chemotherapy. Our data suggest that the Bax-
positive status might identify patients who are likely to respond to such
combination of chemotherapy and to have a longer PFS and OS. Thus,
low expression of Bax was independently associated with poor PFS and
OS, as well as performance status, which has been suggested as an
important prognostic factor in gastric cancer [15,25]. To our knowledge,
this is the first report to explore the prognostic significance of Bax
patients with gastric cancer treated with a three-drug regimen, in which
irinotecan was added to standard platinum- and fluoropyrimidine-
based chemotherapy.
The main limitations of the present study are constituted by the
small sample size and the retrospective, nonrandomized nature.
Technically, specimens were obtained from primary resected tumors
in five of six patients with distant recurrence, and in addition, Bax
expression in the small biopsies may not have been similar to the real
results eventually obtained with surgical specimens. Even if this study
leaves open the possibility that Bax is a prognostic rather than a predic-
tive biomarker of chemotherapy benefit, the correlation with objective
response end point is by itself provocative because the response to third-
generation regimens, such as irinotecan- and oxaliplatin-based combi-
nation, was moderately correlated with PFS but not OS in a published
comprehensive review [26].
Conclusions
In patients with advanced gastric cancer selected for good-intermediate
performance status, Bax expression evaluated by IHC is associated with
a higher likelihood of clinical response to first-line combination with
COI regimen. The outcome of patients with Bax-expressing tumors
and treated with an intensive triplet regimen was promising, with a
median PFS of 8.77 months and a median OS of 23.8 months. Con-
versely, Bax-negative tumors showed an extremely poor clinical out-
come in terms of response and survival.
The results of the current study suggest that patients with gastric
cancer and high expression of Bax might benefit from intensive triplet
chemotherapy COI regimen. Nevertheless, the value of Bax as prognos-
tic factor needs further confirmation by larger and prospective studies.
Above all, its predictive significance should be independently validated
with randomized trials including a control and possibly platinum-free
arm of chemotherapy. In fact, Bax could predict a large-spectrum
Figure 3. OS according to Bax status.
Figure 2. PFS according to Bax status.
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chemoresistance or, more realistically, insensitivity to DNA-damaging
agents, such as platinum derivatives.
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